Matthew J. Wakefield

Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

CountESS: a flexible, graphical pipeline tool for deep mutational scanning analysis.

CountESS: a flexible, graphical pipeline tool for deep mutational scanning analysis.

Journal: bioRxiv : the preprint server for biology

Published: May 07, 2026

RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability.

RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability.

Journal: The EMBO journal

Published: April 30, 2026

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 10, 2025

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Journal: British journal of cancer

Published: April 16, 2025

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Journal: Nature communications

Published: December 23, 2024

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Journal: Clinical and translational medicine

Published: November 27, 2024

MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays.

MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays.

Journal: Genome biology

Published: July 13, 2024

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: Molecular cancer

Published: May 23, 2024

High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers.

High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers.

Journal: NAR cancer

Published: February 20, 2024

Non-canonical RNA substrates of Drosha lack many of the conserved features found in primary microRNA stem-loops.

Non-canonical RNA substrates of Drosha lack many of the conserved features found in primary microRNA stem-loops.

Journal: Scientific reports

Published: November 12, 2023

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

Journal: Cancer discovery

Published: August 03, 2023

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Journal: Therapeutic advances in medical oncology

Published: July 01, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026